id: pea_administration_to_th17_cell_differentiation
name: Palmitoylethanolamide (PEA) Administration â†’ Th17 Cell Differentiation
from_node:
  node_id: pea_administration
  node_name: Palmitoylethanolamide (PEA) Administration
to_node:
  node_id: th17_cell_differentiation
  node_name: Th17 Cell Differentiation
direction: negative
category: biological
mechanism_pathway:
- 'Step 1: PEA lipid mediator is administered as a therapeutic intervention'
- 'Step 2: PEA inhibits expression of master transcription factors required for Th17
  cell differentiation'
- 'Step 3: Reduced transcription factor expression prevents Th17 cell development'
- 'Step 4: Decreased Th17 cells reduces pathogenic T cell responses that cause autoimmune
  diseases'
evidence:
  quality_rating: C
  n_studies: 1
  primary_citation: Yasuhiro Soga et al. 2025. "Lipid mediator palmitoylethanolamide
    (PEA) inhibits pathogenic T cell differentiation in vitro and in vivo.." *Biochemical
    and biophysical research communications*. https://doi.org/10.1016/j.bbrc.2024.151085
last_updated: '2025-12-02'
version: '1.0'
llm_metadata:
  extracted_by: claude-sonnet-4-5-20250929
  extraction_date: '2025-12-02T18:12:07.110771'
  batch_id: msgbatch_01AKnPJgzm7Fk9qubgAz9GaD
